Australia Funds Immunexpress Project to Bring Sepsis MDx Assay to Market | GenomeWeb

NEW YORK (GenomeWeb News) – Australian molecular diagnostics company Immunexpress Group today announced a A$982,707 (US$888,101) grant that it will use to further develop its PCR-based test for sepsis.

The grant comes from Commercialisation Australia, an Australian government initiative, and will go toward Immunexpress' A$2.2 million project to bring its whole blood qRT-PCR test called SeptiCyte Plus to market. The assay is for diagnosing sepsis "within a clinically relevant timeframe," the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.